NCT00119262View on ClinicalTrials.gov

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2009

Conditions
Male Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer
Interventions
DRUG

doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given IV

BIOLOGICAL

bevacizumab

Given IV

DRUG

paclitaxel

Given IV

BIOLOGICAL

filgrastim

Given SC

BIOLOGICAL

pegfilgrastim

Given SC

RADIATION

radiation therapy

Undergo radiation therapy

DRUG

tamoxifen citrate

Given orally

DRUG

aromatase inhibition therapy

Receive aromatase inhibition therapy

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00119262 - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | Biotech Hunter | Biotech Hunter